Back to Search
Start Over
In vitro and in vivo comparison of eravacycline- and tigecycline-based combination therapies for tigecycline-resistant Acinetobacter baumannii
- Source :
- Journal of Chemotherapy. 34:166-172
- Publication Year :
- 2021
- Publisher :
- Informa UK Limited, 2021.
-
Abstract
- Several antimicrobial combination therapies are used to treat multiple drug resistant (MDR) and extensively drug resistant (XDR) Acinetobacter baumannii infections. A novel antibiotic, eravacycline, shows a higher potency than tigecycline. The efficacies of eravacycline-based therapies have not yet been evaluated. We demonstrated the effectiveness of eravacycline- and tigecycline-based combination therapies in XDR and especially tigecycline resistant A. baumannii. Thirteen eligible isolates were selected from 642 non-duplicate Acinetobacter blood isolates from four medical centres in 2010-2014. Tigecycline/imipenem and eravacycline/imipenem combinations were simultaneously effective against some isolates in vitro with fractional inhibitory concentration index of 0.5. In contrast, eravacycline- and tigecycline-based combination therapies provided no additional benefits in mouse survival compared to those for monotherapy. In summary, colistin is still the final resort for XDR-A. baumannii treatment according to the sensitivities. Owning to rapid development of resistance in A. baumannii, novel antibiotics are urgently needed.
- Subjects :
- Pharmacology
Imipenem
biology
business.industry
medicine.drug_class
Antibiotics
Tigecycline
Drug resistance
biochemical phenomena, metabolism, and nutrition
Acinetobacter
bacterial infections and mycoses
biology.organism_classification
Eravacycline
Acinetobacter baumannii
chemistry.chemical_compound
Infectious Diseases
Oncology
chemistry
medicine
Colistin
Pharmacology (medical)
business
medicine.drug
Subjects
Details
- ISSN :
- 19739478 and 1120009X
- Volume :
- 34
- Database :
- OpenAIRE
- Journal :
- Journal of Chemotherapy
- Accession number :
- edsair.doi...........2bd3b9f81d75843e1036fb4f1e1d3ecc